Skip to main content
SpringerLink
Log in

Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy

  • Chapter
  • First Online:
Treatment of Inflammatory Bowel Disease with Biologics

Abstract

Tumor necrosis factor (TNF)-alpha has been established in the innate and acquired immune response in various disease processes, including both Crohn’s disease (CD) and ulcerative colitis (UC). This has led to the development and widespread use of anti-TNF therapies for the management of inflammatory bowel diseases (IBD). Infection, malignancy, antibody development, and infusion reactions are some of the major adverse reactions associated with anti-TNF agents. This review summarizes the evidence, including the limitations of the currently available literature, on various types of malignancy that have been associated with IBD therapies, with a focus upon anti-TNF agents. We highlight the association of anti-TNF agents with melanoma, while thiopurines in combination with anti-TNF agents are more strongly associated with non-melanoma skin cancer (NMSC). Additionally, we discuss the compounded risk of anti-TNFs with immunomodulators in the development of lymphoma and, in particular, the risk of hepatosplenic T-cell lymphoma (HSTCL) in younger patients. We also summarize the limited data on risks of solid tumors and cervical cancer associated with anti-TNF agents. In contrast, we highlight the established reduction in colorectal cancer risk with the use of immunosuppressive agents in IBD that treat inflammatory activity. Finally, we provide recommendations on how to discuss the risks and benefits of anti-TNF agents with patients, emphasizing methods of preventing complications of immunosuppressive medications in IBD. A shared decision-making process in selection of therapies, with appropriate follow-up, monitoring, and continued discussions of risks and benefits, will allow us to effectively and safely treat our patients with IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weinberg JM, Buchholz R. TNF-alpha inhibitors. Basel; Boston: Birkhäuser Verlag; 2006.

    Book  Google Scholar 

  2. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997;40:443–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Mielke ME, Rosen H, Brocke S, et al. Protective immunity and granuloma formation are mediated by two distinct tumor necrosis factor alpha- and gamma interferon-dependent T cell-phagocyte interactions in murine listeriosis: dissociation on the basis of phagocyte adhesion mechanisms. Infect Immun. 1992;60:1875–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Amiri P, Locksley RM, Parslow TG, et al. Tumour necrosis factor alpha restores granulomas and induces parasite egg-laying in schistosome-infected SCID mice. Nature. 1992;356:604–7.

    Article  CAS  PubMed  Google Scholar 

  5. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731–40.

    Article  CAS  PubMed  Google Scholar 

  6. Flynn JL, Goldstein MM, Triebold KJ, et al. IL-12 increases resistance of BALB/c mice to mycobacterium tuberculosis infection. J Immunol. 1995;155:2515–24.

    CAS  PubMed  Google Scholar 

  7. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265–73.e1.

    Article  PubMed  Google Scholar 

  8. Buoy AG, Yoo S, Alam M, et al. Distribution of skin type and skin cancer in organ transplant recipients. Arch Dermatol. 2010;146:344–6.

    Article  PubMed  Google Scholar 

  9. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146:283–7.

    Article  PubMed  Google Scholar 

  10. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–86.

    Article  CAS  PubMed  Google Scholar 

  11. Lindelof B, Sigurgeirsson B, Gabel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143:513–9.

    CAS  PubMed  Google Scholar 

  12. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–91.

    Article  PubMed  Google Scholar 

  13. Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–74.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ekbom A, Helmick C, Zack M, et al. Extracolonic malignancies in inflammatory bowel disease. Cancer. 1991;67:2015–9.

    Article  CAS  PubMed  Google Scholar 

  15. Mellemkjaer L, Olsen JH, Frisch M, et al. Cancer in patients with ulcerative colitis. Int J Cancer. 1995;60:330–3.

    Article  CAS  PubMed  Google Scholar 

  16. Long MD, Kappelman MD, Pipkin CA. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis. 2011;17:1423–7.

    Article  PubMed  Google Scholar 

  17. O’Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871–4.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kopylov U, Vutcovici M, Kezouh A, et al. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a quebec claims database study. Inflamm Bowel Dis. 2015;21:1847–53.

    Article  PubMed  Google Scholar 

  19. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32:2130–5.

    CAS  PubMed  Google Scholar 

  20. Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1431–9.

    Article  Google Scholar 

  21. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology biologics register. Ann Rheum Dis. 2012;71:869–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:210–8.

    Article  PubMed  Google Scholar 

  23. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  24. de La Forest DM, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine. 2016;84(2):133–40.

    Google Scholar 

  25. Olsen CM, Hyrich KL, Knight LL, et al. Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis. Melanoma Res. 2016;26:517–23.

    Article  CAS  PubMed  Google Scholar 

  26. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146–53.

    Article  CAS  PubMed  Google Scholar 

  27. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia. 2000;14:991–7.

    Article  CAS  PubMed  Google Scholar 

  28. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265–7.

    Article  PubMed  Google Scholar 

  29. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–8.

    Article  PubMed  Google Scholar 

  30. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105.

    Article  CAS  PubMed  Google Scholar 

  31. Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406–13.

    Article  PubMed  Google Scholar 

  32. Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2015;74:1087–93.

    Article  CAS  PubMed  Google Scholar 

  33. Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin. 2015;31:557–74.

    Article  CAS  PubMed  Google Scholar 

  34. Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014;43:489–97.

    Article  CAS  PubMed  Google Scholar 

  35. Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers – United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65:661–6.

    Article  PubMed  Google Scholar 

  36. Rungoe C, Simonsen J, Riis L, et al. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13:693–700.e1.

    Article  PubMed  Google Scholar 

  37. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631–6.

    Article  PubMed  Google Scholar 

  38. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136:451–8.

    Article  PubMed  Google Scholar 

  39. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807–16.

    Article  CAS  PubMed  Google Scholar 

  40. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29:2727–37.

    PubMed  Google Scholar 

  41. Mellemkjaer L, Johansen C, Gridley G, et al. Crohn's disease and cancer risk (Denmark). Cancer Causes Control. 2000;11:145–50.

    Article  CAS  PubMed  Google Scholar 

  42. Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut. 1994;35:1507–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11:1601–8.e1-4.

    Article  PubMed  Google Scholar 

  44. Carrat F, Seksik P, Colombel JF, et al. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;45(4):533–41.

    Article  PubMed  Google Scholar 

  45. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235–40.

    Article  PubMed  Google Scholar 

  46. Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58–64.

    Article  CAS  PubMed  Google Scholar 

  47. Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151(1):97–109.e4.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2010;16:2168–72.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Campus Box 7080, Chapel Hill, NC, 27599-7080, USA

    Julia T. Hughes & Millie D. Long

  2. Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Campus Box 7080, Chapel Hill, NC, 27599-7080, USA

    Julia T. Hughes & Millie D. Long

Authors
  1. Julia T. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Millie D. Long
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia T. Hughes .

Editor information

Editors and Affiliations

  1. Beth Israel Deaconess Medical Center Center for Inflammatory Bowel Disease, Harvard Medical School, Boston, Massachusetts, USA

    Adam S. Cheifetz

  2. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

    Joseph D. Feuerstein

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Hughes, J.T., Long, M.D. (2018). Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy. In: Cheifetz, A., Feuerstein, J. (eds) Treatment of Inflammatory Bowel Disease with Biologics . Springer, Cham. https://doi.org/10.1007/978-3-319-60276-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-60276-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-60275-2

  • Online ISBN: 978-3-319-60276-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation